The information provided herein is generated by experimental artificial intelligence and is for informational purposes only.
viking therapeutics oral obesity drug shows promising early weight loss results
Viking Therapeutics' oral obesity drug has shown promising results, with an average weight loss of about 8% after four weeks at the highest dose, raising expectations among analysts. Despite a 9% drop in shares following the announcement, experts noted the data's potential, comparing it favorably to competitors like Wegovy and Zepbound. Viking plans to initiate a Phase 2 study later this year while advancing its injectable version to Phase 3 trials.
novo seeks approval for semaglutide as treatment for liver disease
Novo Nordisk plans to seek regulatory approval for semaglutide as a treatment for metabolic dysfunction-associated steatohepatitis (MASH) after positive Phase 3 trial results. The study showed significant improvements in liver scarring and resolution of MASH among patients receiving semaglutide compared to placebo. Despite the promising findings, analysts remain cautious about its competitive edge in the MASH treatment landscape.
Seems like the connection with the server has been lost. It can be due to poor or broken network. Please hang on while we're trying to reconnect...
Oh snap! Failed to reconnect with the server. This is typically caused by a longer network outage, or if the server has been taken down. You can try to reconnect, but if that does not work, you need to reload the page.
Oh man! The server rejected the attempt to reconnect. The only option now is to reload the page, but be prepared that it won't work, since this is typically caused by a failure on the server.